RxDoctor Payments Data

John Liu, MD

Ophthalmology · Riverside, CANPI 1457732661

Payments from drug & device makers

$2,156in general payments, 2019–2025

Across 27 payments — averaging $79.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$1K
  • Alcon$244
  • Shire North American Group Inc$112
  • Johnson & Johnson Surgical Vision, Inc.$89
  • Viiv Healthcare Company$83
  • Sight Sciences, Inc.$46
  • plus $182 from 6 others

What the payments were for

  • Consulting fees$1,29060%
  • Food & beverage$86640%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,156 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$70,014
Medicare patients
221
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine106$74,122
XiidraLifitegrast102$68,476
Cyclosporine202$61,139
MieboPerfluorohexyloctane/Pf27$22,314
Prednisolone Acetate429$21,997
TyrvayaVarenicline Tartrate13$10,290
RocklatanNetarsudil Mesylat/Latanoprost14$6,380
Brimonidine Tartrate102$5,895
Travoprost19$5,362
TobradexTobramycin/Dexamethasone19$4,891
Latanoprost351$4,625
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,714
Ofloxacin313$3,373
Diclofenac Sodium283$2,820
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$2,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$37$90,790129 claims
AbbVieRestasis$28$74,122106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →